Recruitment unclearEUCTR 2008-008918-39
BRAIN DERIVED NEUROTROPHIC FACTOR AND MAJOR DEPRESSIVE DISORDER TREATMENT: CLINICAL PSYCHOLOGICAL AND PSYCHOPHARMACOTHERAPIC EVALUATIONS
This historical record does not confirm current site availability.
Historical research recordItalyDepression
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Italy
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Italy
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2008-008918-39
- Official title
Show the full official title
BRAIN DERIVED NEUROTROPHIC FACTOR AND MAJOR DEPRESSIVE DISORDER TREATMENT: CLINICAL PSYCHOLOGICAL AND PSYCHOPHARMACOTHERAPIC EVALUATIONS
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Italy
Registry details
Historical country statuses
- Italy — Ongoing
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO".
Want to explore more studies?
Explore studiesRelated studies
A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensiv...
A RANDOMIZED, 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLEXIBLE DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN CHILDREN AND ADOLESCENT SUBJECTS WITH BIPOLAR I DEPR...